bouchardatine

syntheic from Bouchardatia neurococca; structure in first source

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

1.	Rectal Neoplasms (Rectal Cancer) 07/05/2019 - "The present study identified bouchardatine (Bou) as a potent suppressor of rectal cancer growth by cycle-arresting independent of apoptosis. " 07/05/2019 - "Bouchardatine suppresses rectal cancer in mice by disrupting its metabolic pathways via activating the SIRT1-PGC-1α-UCP2 axis."
2.	Obesity 01/01/2017 - "The present study evaluated the therapeutic effects of the newly identified bouchardatine (Bou) on obesity-associated metabolic disorders and the molecular mechanisms of these effects. "
3.	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/01/2019 - "R17 derived from bouchardatine, shows benefits in the metabolic syndrome, but has not been tested in the liver. "
4.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2023 - "We previously found a natural product, bouchardatine, modulated aerobic metabolism and inhibited proliferation in the colorectal cancer cell (CRC). " 01/01/2023 - "Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer."
5.	Alcoholic Fatty Liver 01/01/2019 - "Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity."

1.	Therapeutic Uses
2.	AMP-Activated Protein Kinases
3.	Adenosine Triphosphate (ATP)